Founded in 2001, Trophogen, Inc. is a biotechnology company based in Rockville, Maryland. The company's core mission is to improve human and animal health through advanced protein engineering. Trophogen specializes in developing patented, long-acting, potent, and non-immunogenic superagonist analogs of glycoprotein hormones and growth factors. Their market focus includes both human and veterinary medicine, aiming to provide more effective and safer therapeutic options.

Notable figures associated with Trophogen include Bruce Weintraub, who serves as COO & CSO, and Mariusz Szkudlinski, the VP of Research and Development. The company has achieved significant milestones in creating a broad platform technology that enhances the efficacy and safety of hormone and growth factor treatments. Trophogen's innovations have had a substantial impact on the biotechnology industry, offering promising advancements in medical treatments for various health conditions.